Tthe U.S. Food and Drug Administration (FDA) has granted approval to WAINUA™ (eplontersen), a pioneering therapy for hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN) in adults. This regulatory milestone is anchored in the compelling data from the Phase 3 NEURO-TTRansform study. WAINUA™ emerges as the first and only FDA-approved treatment for hATTR-PN that patients can self-administer using an auto-injector. The efficacy of WAINUA™, as evidenced in the study’s findings published in The Journal of the American Medical Association (JAMA), demonstrates its consistent impact in arresting the progression of neuropathic disease and enhancing patient-reported outcomes related to neuropathy impairment and overall quality of life.

mRNA Advancement in Neurology
Hereditary transthyretin-mediated amyloid polyneuropathy, a progressive and life-threatening disease, is known for causing severe peripheral nerve damage and motor disability. Left untreated, hATTR-PN often leads to fatal outcomes within a decade of diagnosis. WAINUA™, a ligand-conjugated antisense oligonucleotide (LICA) medicine, innovatively targets the reduction of transthyretin (TTR) protein production. This strategic approach directly combats the underlying cause of the disease, offering new hope for those affected. With the FDA’s approval, WAINUA™ is expected to be available in the U.S. from January 2024.

This FDA approval marks a crucial milestone in treating rare, debilitating diseases. WAINUA™’s introduction is particularly significant, considering the urgent need for effective treatments in the realm of rare neurological disorders. Its self-administered format via an auto-injector not only enhances ease of use but also empowers patients in managing their treatment. The success of WAINUA™ is a testament to the relentless pursuit of innovation in addressing challenging medical conditions.

Looking beyond hATTR-PN, the potential of WAINUA™ extends to other related conditions. Notably, a large-scale Phase 3 CARDIO-TTRansform study is currently underway for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), a condition impacting the heart and typically leading to progressive heart failure. This study, the largest in this patient population to date, is set to provide further insights into the broader applicability of eplontersen, potentially opening new avenues for treatment in related diseases.

The FDA’s endorsement of WAINUA™ for hATTR-PN treatment heralds a new era in the management of rare neuron diseases, showcasing the power of targeted genetic therapies. As WAINUA™ becomes available to patients, it stands as a beacon of hope, not only for those battling hATTR-PN but also for the wider community affected by similar genetic disorders. This approval is a crucial step forward in the ongoing journey to provide more effective, patient-centered treatments for complex, rare diseases.

Related News

Related Services

Plasmid CDMO Services

We provide high quality plasmids that are ideal for any phase of the drug development cycle.


AAV cGMP Manufacturing

Ranging from pilot to industrial-scale AAV packaging for both in vitro and in vivo studies.


aav icon

AAV Capsid Engineering

Proven technology paving your path to effective therapies for cancer or genetic disorder